Head-to-head evidence
SG301 vs TJ202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
SG301
Developed by Hangzhou Sumgen Biotech Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06508983 (registry estimate)
TJ202
Developed by TJ Biopharma Co., Ltd.
NCT03952091 · Phase 3 · completed
The study randomly assigned 289 participants to TJ202 plus lenalidomide and dexamethasone or to the active comparator regimen, but it was open-label rather than blinded. Its primary endpoint was the clinical measure of progression-free survival; because no results are posted, it is not possible to determine whether this endpoint was met.
Systemic Lupus Erythematosus
Shared mechanism: CD38 · full Systemic Lupus Erythematosus pipeline
SG301
Developed by Hangzhou Sumgen Biotech Co., Ltd.
NCT06144710 · Phase 1 · completed
This early-phase study is mainly designed to establish safety and dosing for SG301: the healthy-volunteer portion is open-label and uncontrolled, while the lupus-patient portion is randomized and placebo-controlled but enrolls only a small number of patients per dose group. Clinical disease-activity improvement is a secondary rather than primary measure, and no results have been posted.
Next expected readout: September 2027 · NCT07447986 (registry estimate)
TJ202
Developed by TJ Biopharma Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SG301's landscape · TJ202's landscape